|
|
 |
|
Important |
|
|
Product Safety Information |
|
|
|
|
|
|
|
|
|
|
 |
Neulasta® is indicated to decrease the incidence of infection,
as manifested by febrile neutropenia, in patients with nonmyeloid malignancies
receiving myelosuppressive anticancer drugs associated with a clinically significant
incidence of febrile neutropenia. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
